Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MTRX1011A in Patients With Rheumatoid Arthritis

This study has been terminated.
(Study had completed enrollment but drug injection was halted due to an unacceptable incidence of rash.)
Sponsor:
Information provided by (Responsible Party):
Genentech, Inc.
ClinicalTrials.gov Identifier:
NCT00718588
First received: July 16, 2008
Last updated: March 6, 2012
Last verified: March 2012

July 16, 2008
March 6, 2012
July 2008
December 2009   (final data collection date for primary outcome measure)
Safety and tolerability of MTRX1011A in both the SAD and MAD stages [ Time Frame: Length of study ] [ Designated as safety issue: Yes ]
Safety and tolerability of MTRX1011A in both the SAD and MAD stages [ Time Frame: Length of study ]
Complete list of historical versions of study NCT00718588 on ClinicalTrials.gov Archive Site
  • Characterize the pharmacokinetic response of MTRX1011A [ Time Frame: Length of study ] [ Designated as safety issue: Yes ]
  • Characterize the pharmacodynamic profile of single and multiple doses of MTRX1011A [ Time Frame: Length of study ] [ Designated as safety issue: Yes ]
  • Characterize the pharmacokinetic response of MTRX1011A [ Time Frame: Length of study ]
  • Characterize the pharmacodynamic profile of single and multiple doses of MTRX1011A [ Time Frame: Length of study ]
Not Provided
Not Provided
 
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MTRX1011A in Patients With Rheumatoid Arthritis
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial, With a Single Ascending-Dose Stage Followed by a Multiple Ascending-Dose Stage, of the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous MTRX1011A in Patients With Rheumatoid Arthritis

This is a Phase I multicenter study that will be conducted in the United States and consists of a double-blind, placebo-controlled, SAD stage, followed by a double-blind, placebo controlled MAD stage. The study will be conducted in approximately 65 adult patients between 18 and 80 years old who have RA.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Rheumatoid Arthritis
Drug: MTRX1011A
Subcutaneous and intravenous single and repeating dose
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
66
Not Provided
December 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. SAD Stage

    • RA diagnosed according to the ACR
    • For patients taking anti-rheumatic therapies, receipt of a stable regimen prior to randomization
    • Previous treatment with biologic agents, including anti-TNF agents, permitted but discontinued for an appropriate washout period
  2. MAD Stage (same as above with the addition of the following)

    • Failure of at least one biologic agent, defined as lack of or loss of response or intolerance
    • Active disease defined by swollen and tender count

Exclusion Criteria:

  • Significant systemic involvement of RA, including vasculitis, pulmonary fibrosis, or Felty's syndrome
  • Malignancy, or prior malignancy, other than non-melanoma skin cancer or cervical carcinoma in situ that has been resected
  • History of treatment with any T cell-directed therapy
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00718588
CDT4478g
Not Provided
Genentech, Inc.
Genentech, Inc.
Not Provided
Study Director: John Davis, M.D., M.P.H. Genentech, Inc.
Genentech, Inc.
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP